Title : Advancing therapeutics: Translational approaches in drug development

The successful translation of scientific discoveries into clinically effective therapies remains a major challenge in contemporary drug development, with high attrition rates often resulting from suboptimal target selection, inadequate dose optimization, and limited understanding of human variability. Clinical pharmacology occupies a central position in addressing these challenges by providing a quantitative and mechanistic framework that links drug exposure to pharmacological response across the translational continuum. Advancing Therapeutics: Translational Approaches in Drug Development explores the critical role of clinical pharmacology in transforming promising compounds into safe, efficacious, and patient-centered medicines. This presentation emphasizes the integration of pharmacokinetics and pharmacodynamics (PK–PD), exposure–response analyses, and biomarker-based strategies to guide rational decision-making from first-in-human studies through late-phase clinical development. Model-informed drug development (MIDD) approaches; including population pharmacokinetic modeling, physiologically based pharmacokinetic (PBPK) modeling, and quantitative systems pharmacology are highlighted as essential tools for predicting human pharmacology, optimizing dose selection, and reducing uncertainty during clinical progression. These methods support the identification of therapeutic windows, inform special population dosing, and enhance translational confidence between preclinical and clinical findings. The abstract further examines the contribution of pharmacogenomics and variability assessment in improving therapeutic precision and minimizing adverse drug reactions. Adaptive clinical trial designs and real-time data integration are discussed as innovative strategies that enable efficient hypothesis testing and iterative learning within clinical programs. In addition, the evolving role of real-world evidence and regulatory science is considered in strengthening benefit–risk evaluation and supporting regulatory decision-making.

By embedding clinical pharmacology principles at the core of translational research, drug development programs can achieve greater efficiency, predictability, and patient relevance. Ultimately, translational approaches anchored in clinical pharmacology accelerate the delivery of innovative therapeutics, address unmet medical needs, and enhance global health outcomes through evidence-based, mechanism-driven development strategies.

Dr. Oladejo Afees Adebayo is a Nigerian biochemist, researcher, and university lecturer at Nnamdi Azikiwe University, Awka. He holds a Ph.D. in Biochemistry with specialization in medical biochemistry, toxicology, and experimental research. His scholarly work focuses on cardiovascular diseases, oxidative stress, natural product therapeutics, and nutritional biochemistry, with over 50 peer-reviewed publications. A recipient of the TETFund Institutional-Based Research Grant, Dr. Oladejo is actively involved in teaching, research supervision, academic leadership, and professional service within national and international scientific communities.